Browsing Category
Pharma Industry News
4744 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.
Merck to acquire Verona Pharma for $10bn, securing Ohtuvayre COPD therapy
Verona Pharma stock jumps 20% as Merck announces $10B acquisition to boost its COPD pipeline with first-in-class therapy Ohtuvayre. Read full analysis.
Rhythm Pharmaceuticals (RYTM) surges 35% after announcing Phase 2 trial data reveal for oral MC4R agonist bivamelagon
Find out why Rhythm Pharmaceuticals stock surged over 35% and what the upcoming bivamelagon trial results mean for its rare disease pipeline.
MHRA approves Bayer’s Lynkuet as first non-hormonal treatment for menopause hot flushes
Bayer’s Lynkuet becomes the world’s first approved non-hormonal menopause pill. Find out what MHRA’s decision means for women’s health today.
Bonerge initiates clinical trial evaluating Urolithin A and Fisetin for age-related sleep disruptions
Bonerge begins a clinical trial on Urolithin A and Fisetin for sleep quality, marking a shift toward evidence-backed anti-ageing and circadian rhythm restoration.
Sagent Pharmaceuticals and Qilu Pharmaceutical sign $4.5bn injectable drug deal to boost U.S. hospital supply access
Sagent Pharmaceuticals signs $4.5B deal with Qilu Pharmaceutical to boost U.S. access to complex injectable drugs, improving affordability and supply resilience.
NYB.AI and Pnaseer Inc. partner on AI-driven hair follicle regeneration drug discovery
NYB.AI and Pnaseer Inc. partner on Project Follica to develop AI-powered hair regeneration therapies with targeted nanoparticle delivery. Read the full strategy.
BlueRock Therapeutics and Bayer dose first patient in clinical trial of iPSC-derived OpCT-001 therapy for vision loss
BlueRock Therapeutics and Bayer AG have dosed the first patient in their Phase 1/2a CLARICO trial of OpCT-001, a novel iPSC-derived therapy targeting primary photoreceptor diseases.
InnoCare Pharma receives Chinese IND clearance for novel B7-H3 targeted ADC ICP-B794 to treat solid tumors
InnoCare Pharma gains Chinese IND approval for ICP-B794, a novel B7-H3 targeted ADC for solid tumors including lung and prostate cancer.
Neurizon Therapeutics secures global licence from Elanco to fast-track NUZ-001 commercialisation
Find out how Neurizon’s global licence with Elanco is accelerating ALS therapy NUZ-001 and de-risking its path to market entry and clinical trials.